Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia

Journal of Lipid Research

Volumn 42, Issue 8, 2001, Pages 1239-1249

  Campos, Hannia ^a   Perlov, Dan ^a   Khoo, Christina ^a   Sacks, Frank M ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cholesterol; Metabolism; Triglyceride

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; CHOLESTEROL; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CHOLESTEROL METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; IMMUNOAFFINITY CHROMATOGRAPHY; LIPID METABOLISM; MALE; PARTICLE SIZE; PRIORITY JOURNAL;

APOLIPOPROTEIN C-III; APOLIPOPROTEINS B; APOLIPOPROTEINS C; APOLIPOPROTEINS E; CHROMATOGRAPHY, AFFINITY; FEMALE; GENOTYPE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPOPROTEINS; LIPOPROTEINS, IDL; LIPOPROTEINS, LDL; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; SEX CHARACTERISTICS; ULTRACENTRIFUGATION;

EID: 0034891033     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein
2. Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III
3. Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoprotein lipase from different sources
4. Further observations on the activation and inhibition of lipoprotein lipase by apolipoproteins
5. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins C-III and AI. Evidence that apolipoprotein C-III inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo
6. Further characterization of the metabolic properties of triglyceride-rich lipoproteins from human and mouse apoC-III transgenic mice
7. Effect of apoproteins on hepatic uptake of triglyceride emulsions in the rat
8. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E and individual C apoproteins
9. The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat
10. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) C-III transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo C-III and reduced apo E on the particles
11. Influence of apolipoprotein E on soluble and heparinimmobilized hepatic lipase
12. Lipoprotein metabolism during acute inhibition of lipoprotein lipase in the cynomolgus monkey
13. Lipoprotein metabolism in hepatic lipase deficiency: Studies on the turnover of apolipoprotein B and on the effect of hepatic lipase on high density lipoprotein
14. Apolipoproteins C-II and C-III metabolism in hypertriglyceridemic patients. Effect of a drastic triglyceride reduction by combined diet restriction and fenofibrate administration
15. Hypertriglyceridemia as a result of human apo C-III gene expression in transgenic mice
16. Targeted disruption of the apolipoprotein C-III gene in mice results in hypotriglyceridemia and protection from postprandial hypertriglyceridemia
17. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction
18. Hypertriglyceridemia as a cardiovascular risk factor
19. A biochemical and morphologic study of very low density lipoproteins in carbohydrate-induced hypertriglyceridemia
20. The isolation and quantitative analysis of serum lipoproteins
21. Heterogeneity of human plasma very low density lipoproteins. Separation of species differing in protein components
22. Changes in plasma very low density and low density lipoprotein content, composition, and size after a fatty meal in normo- and hypertriglyceridemic man
23. Structural and metabolic heterogeneity of β-very low density lipoproteins from cholesterol-fed dogs and from humans with type III hyperlipoproteinemia
24. Metabolism of human intermediate and very low density lipoprotein subfractions from normal and dysbetalipoproteinemic plasma. In vivo studies in the rat
25. Isolation and characterization of two distinct species of human very low density lipoproteins lacking apolioprotein E
26. The influence of apolipoprotein E on the interactions between normal human very low density lipoproteins and U937 human macrophages: Heterogeneity among persons
27. ApoE is necessary and sufficient for the binding of large triglyceride-rich lipoproteins to the LDL receptor; apoB is unnecessary
28. Triglyceride-rich lipoproteins and atherosclerosis: Pathophysiotogical considerations
29. Apolipoprotein E-enriched lipoprotein subclasses in normolipidemic subjects
30. Human very low density lipoprotein structure: Interaction of the C apolipoproteins with apolipoprotein B-100
31. Determinants of hepatic uptake of triglyceride-rich lipoproteins and their remnants in the rat
32. Heterogeneity of very-low-density lipoprotein metabolism in hyperlipidemic subjects
33. Roles of apolipoproteins B and E in the cellular binding of very low density lipoproteins
34. Distinct murine macrophage receptor pathway for human triglyceride-rich lipoproteins
35. Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women
36. Logistic discriminant analysis of lipids and apolipoproteins in a population of coronary bypass patients and the significance of apolipoproteins G-III and E
37. Apolipoproteins C-III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: The ECTIM study
38. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass graphs
39. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin
40. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial
41. VLDL, apolipoproteins B, C-III, and E, and risk of recurrent coronary events in the cholesterol and recurrent events (CARE) trial
42. Significance of apolipoproteins for structure, function, and classification of plasma lipoproteins
43. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density, lipoprotein receptor-related protein
44. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: Comparison of the apoC-III to apoE ratio in different lipoprotein fractions
45. The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding
46. Apolipoprotein E mediates binding of normal very low density lipoprotein to heparin but is not required for high affinity receptor binding
47. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins
48. VLDL receptor mediates the uptake of human chylomicron remnants in vitro
49. Plasma apolipoprotein A-I, A-II, B, E and C-III containing particles in men with premature coronary artery disease
50. Enrichment with apolipoprotein E characterizes postprandial TG-rich lipoproteins in patients with non-insulin-dependent diabetes mellitus and coronary artery disease: A preliminary report
51. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low-density lipoprotein receptor pathway
52. Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content
53. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI
54. Phenotypic expression of heterozygous lipoprotein lipase deficiency in the extended pedigree of a proband homozygous for a missense mutation
55. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene
56. Lipoprotein lipase: A multifunctional enzyme relevant to common metabolic diseases
57. Increased expression of apolipoprotein E in transgenic rabbits results in reduced levels of very low density lipoproteins and an accumulation of low density, lipoproteins in plasma
58. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia
59. Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo
60. Differential metabolism of human VLDL according to context of apolipoprotein E and C-III